Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that its computation chemistry platform technology will be presented at NVIDIA’s GTC 2025 Japan AI Day to be held on March 21, 2025 JST (March 20, 2025 PDT).

GTC is a global conference for cutting-edge AI and robotics technologies organized by NVIDIA, one of the world’s largest GPU semiconductor manufacturers and a leader in HPC and AI development. GTC 2025 will be held March 17-21 in San Jose and Japan AI Day will be held virtually on the last day of the conference in order to introduce the latest AI applications and R&D across various industries in Japan.

Alivexis’ CSO, Dr. Yoh Terada, will give a presentation entitled “Integrating HPC & AI: The Future of AI Drug Discovery Using Scaled and High Quality Synthetic Data.” This lecture will introduce the latest version of Alivexis’ computational drug discovery platform, ModBind™, and will discuss the performance of its proprietary drug discovery AI algorithm trained on highly accurate synthetic data generated by ModBind™.

Participation in the GTC 2025 Japan AI Day is free of charge and registration is open now on the NVIDIA GTC 2025 event page.

Date of presentation: March 20th, 2025 10:00-10:40PM (PDT)
March 21st, 2025 14:00-14:40 (JST)
Session abstract: Link

Alivexis To Present at GTC 2025 Japan AI Day(PDF)